RecruitingNCT04272658

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

Interest in PET/CT Whole-body Dynamic Acquisition at FDG to Differentiate Progression/Pseudo Progression of Metastatic Melanoma Under Immunotherapy

Sponsor

University Hospital, Brest

Enrollment

56 participants

Start Date

Jun 26, 2020

Study Type

OBSERVATIONAL

Conditions

Metastatic Melanoma

Summary

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a special type of full-body scan (PET/CT) to better understand how immunotherapy drugs are working in people with advanced skin cancer (melanoma). Researchers want to see whether a dynamic whole-body imaging approach can better track the cancer's response to treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with metastatic melanoma (melanoma that has spread) - You are currently being treated with an immunotherapy drug such as Nivolumab, Pembrolizumab, or a combination of Ipilimumab and Nivolumab **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are under 18 - You have a different type of cancer - You decline to participate Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your Doctor Check Your Eligibility

Interventions

DIAGNOSTIC_TESTvalue of 4D body-to-whole dynamic acquisition in FDG

differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this "unconfirmed progression" after 2 new treatment cures of ICI

Locations(1)

Hospital University ff Brest

Brest, Finistere, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04272658

Related Trials

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

NCT05136196221 locations

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

NCT0589683926 locations

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT041190243 locations

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT052693811 location

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT0565531213 locations